AstraZenecon has submitted a clinical application for a new generation of oral estrogen-influenced antagonists

AZD9833 belongs to a new generation of oral selective estrogen inhibitors (ER alpha) antagonists and degradation agents (SERDs).
can inhibit the growth of tumor cells driven by ER alpha and lead to degradation of ER alpha receptors.
Phase I clinical study code-named SERENA-1 evaluated the tolerance and efficacy of AZD9833 treatment with ≥1 endocrine therapy and ≤2 chemotherapy for pre- and post-menotinal ER-HER2-advanced breast cancer patients.
24 weeks, the overall objective remission rate (ORR) was 16.3% and the clinical benefit rate (CBR) was 42.3%.
rate ≥10% adverse reactions include: visual impairment (53%, G3:3%), titration or sinus titration (45%), nausea (18%), fatigue (13%), dizziness (10%, G3:17%), vomiting (10%, G3:17%), fatigue (10%).
fluorovis group is the only approved Er alpha selective degradation agent, but the way intramuscular injections are given limits clinical applications.
the launch of the AZD9833 oral preparation will greatly improve patient compliance.
content Source: Medical Rubik's Cube Info